Core Viewpoint - The National Medical Products Administration (NMPA) is optimizing the review and approval process for urgently needed foreign drugs already on the market to meet the pressing clinical needs of patients in China [1][2]. Group 1: Regulatory Changes - The NMPA will enhance the review mechanism and accelerate the review speed while improving the inspection system to reflect the characteristics of various drug types [2]. - The NMPA encourages applicants to conduct global synchronous research and simultaneous application for market approval in China for urgently needed foreign drugs [1]. Group 2: Market Performance - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024 [2]. - The total amount of authorized transactions for innovative drugs in 2025 exceeded $130 billion, with over 150 transactions, marking another historical high [2]. Group 3: Drug Composition - The 76 innovative drugs approved in 2025 include 47 chemical drugs, 23 biological products, and 6 traditional Chinese medicines [2]. - Among the 47 chemical drugs, 38 are domestic innovations, and 9 are imported, with domestic innovations accounting for 80.85% [2]. - For the 23 biological products, 21 are domestic innovations, and 2 are imported, with domestic innovations making up 91.30% [2]. Group 4: Industry Outlook - The release of the first version of the "Commercial Health Insurance Innovative Drug Directory" in December 2025 establishes a multi-layered payment system, creating new market pathways for high-value innovative drugs [2]. - Industry insiders are optimistic about 2026, anticipating a surge in innovative drug business development (BD) due to supportive industrial policies for true and high-level innovations [2]. - The dual push from commercial insurance implementation and procurement optimization is expected to sustain high prosperity in the innovative drug industry, with high-value innovative drugs likely to experience a second growth curve [2]. Group 5: Key Companies - Notable companies in the Hong Kong innovative drug sector include: Heng Rui Medicine, Kelun-Botai Biological, and others [3]. - Leading companies in the CXO sector include: Kailai Ying, Kanglong Chemical, and others [4].

重大事项： 赛目科技(02571)拟为浙江赛目科技引入战投1200.98万元 构建全链条汽车电子仿真业务能力 毛戈平(01318)与路威凯腾签订战略合作框架协议 天工国际(00826)：镇江乾元拟代价1.8亿元将其持有的1.76%天工工具股权转让给天工新材 恒瑞医药(01276)：瑞拉芙普α注射液获得药品注册批准 正通汽车(01728)：启富集团拟8.03亿元出售深圳汇安启全部股权 聚焦汽车主业转型 同源康医药-B(02410)：甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评 景联集团(01751)附属就苏尼特右旗新蒙新材料有限公司工业废气发电专案二期工程订立工程承包协定 经营业绩： 极兔速递-W(01519)2025年包裹量合计301.287亿件，同比增长22.2% 和黄医药(00013)宣布索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血的 ESLIM-02中国研究的III期 阶段取得阳性顶线结果 中国碳中和(01372)与中国铁塔及中国再生资源签署三方战略合作协议 联合打造锂电循环经济生态圈 丽珠医药(01513)：莱康奇塔单抗注射液被纳入优先审评审批程序 秦港股份(03369)：2025年度吞吐量总 ...

Core Viewpoint - The Chinese innovative pharmaceutical industry is undergoing a historic transformation, shifting from "fast followers" to "original creators," supported by solid data and market performance [1]. Group 1: Industry Overview - China's pharmaceutical industry is the second largest globally, with innovative drugs accounting for approximately 30% of global research [1]. - By 2025, the total value of innovative drug licensing transactions in China is expected to exceed $130 billion, with over 150 transactions, marking historical highs [1]. - The increase in competitiveness and cost-effectiveness of Chinese pharmaceutical assets is driving the industry into a critical phase of "innovation realization + global layout" [1]. Group 2: Regional Development - Shanghai's Pudong district is becoming a core hub for the global market connection of China's biopharmaceutical industry, with significant achievements in innovative drug approvals and business development transactions [1]. - By 2025, Pudong has approved 4 CAR-T products (30% of the global total) and 7 Class 1 new drugs (14% of the national total), with business development transaction amounts reaching $20.4 billion (14% of the global total) [1]. Group 3: Competitive Advantages - Chinese innovative pharmaceutical companies are gaining a competitive edge in the global market due to their speed and cost-effectiveness, being able to advance drug discovery 2-3 times faster and recruit clinical trial patients 2-5 times faster than international counterparts [3]. - The cost per patient for clinical trials in China is only half that of Europe and the US [3]. Group 4: Business Development Collaborations - Companies like Maiwei Biopharma and Jinsai Pharmaceutical are forming significant overseas business development collaborations, enhancing China's global competitiveness in innovative drugs [3][5]. - Maiwei Biopharma has accelerated its business development efforts, securing exclusive licensing agreements for innovative therapies within months of initial meetings [3][4]. Group 5: Full-Chain Layout - A number of innovative pharmaceutical companies are rapidly constructing comprehensive overseas layouts covering research, registration, and sales, transitioning from "licensing out" to "commercialization abroad" [9]. - By 2024, Pudong is expected to have over 20 innovative drugs achieving commercial sales, with total sales exceeding 11.6 billion yuan [9]. Group 6: Source Innovation - The market consensus is that only companies with source innovation capabilities, quality business development potential, and global layout abilities can effectively meet global market demands and achieve high valuations [16]. - Companies like Jinfang Pharmaceutical are focusing on unique therapeutic areas and avoiding following trends, which positions them favorably in the global market [17]. Group 7: Industry Ecosystem - The rise of China's innovative pharmaceutical industry is attributed to years of policy guidance, technological accumulation, and capital cultivation, leading to a critical growth inflection point [21]. - The unique industrial atmosphere, quality talent pool, and complete industrial chain in Zhangjiang are considered core advantages for companies operating in the region [21][22]. Group 8: Future Outlook - The Pudong district is set to enhance its support for the biopharmaceutical industry, aiming to become a global hub for innovative drug launches and scientific entrepreneurship [23]. - The ongoing development of a differentiated industrial linkage pattern is expected to further support the growth of the life sciences industry in the region [23]. Group 9: Conclusion - The path of globalization for Chinese innovative drugs is deepening, supported by core industrial hubs like Pudong and the continuous upgrading of companies' innovation and internationalization capabilities [24].

Core Viewpoint - The Hong Kong stock market is experiencing significant growth in the biopharmaceutical sector, with the innovative drug ETF showing strong performance and trading activity [1][2]. Group 1: Market Performance - The Hong Kong innovative drug ETF (159567) increased by 3.27%, with a trading volume exceeding 1.207 billion yuan and a turnover rate over 14% [1]. - Notable individual stocks include Tongyu Kang Pharmaceutical-B rising over 11%, Ascentage Pharma-B up over 7%, and Kangfang Biotech increasing over 6% [2]. Group 2: Industry Growth - By 2025, China's innovative drug business development (BD) is expected to see explosive growth, with total foreign licensing transaction amounts reaching $135.655 billion (approximately 948.3 billion yuan) and a record 157 transactions [2]. - China has surpassed the United States to become the world's largest source of drug licensing, with 90% of the top 20 global multinational pharmaceutical companies collaborating with Chinese innovative drug pipelines [2]. Group 3: Policy Support - The implementation of a dual directory for medical insurance and commercial insurance will begin on January 1, 2026, adding 114 new drugs to the basic medical insurance directory, including 50 first-class innovative drugs [2]. Group 4: Technological Advancements - The integration of AI is accelerating the drug development process, with companies like Insilico Medicine significantly shortening the candidate compound identification cycle [2]. - The commercialization of cutting-edge fields such as ADC, bispecific antibodies, and small nucleic acids is accelerating, with 76 innovative drugs expected to be approved in China by 2025, surpassing the 48 expected in 2024 [2]. Group 5: ETF Composition - The Hong Kong innovative drug ETF closely tracks the Guozheng Hong Kong Stock Connect Innovative Drug Index, featuring leading stocks such as BeiGene, Innovent Biologics, and 3SBio, with a high proportion of innovative pharmaceutical companies [2].

Group 1 - Kangfang Biotech (09926) shares rose over 6% after the approval of an important update to the product label for its PD-1/VEGF bispecific antibody, Ivosidenib, which showed significant clinical benefits in treating advanced non-squamous non-small cell lung cancer [1] - Sunac China (01918) shares fell over 6% as the company reported a contract sales amount of 2.95 billion RMB in December, a year-on-year increase of 68.6%, but with a decrease in average sales price per square meter by 14.4% [1] - Nanshan Aluminum International (02610) saw a nearly 14% increase in shares, attributed to a tight global electrolytic aluminum market, with Indonesia being a key marginal supplier [1] Group 2 - Optical communication stocks rebounded, with Longi Fiber Optic (06869) up 7.46% and Cambridge Technology (06166) up 3.86%, following a significant rise in U.S. optical communication stocks [2] - Hengrui Medicine (01276) shares increased over 2.8% after announcing the approval of two innovative drugs for clinical trials targeting prostate cancer [2] - Cao Cao Travel (02643) shares rose over 7% following the announcement of acquisitions of Yao Travel and Geely Business Travel [2] Group 3 - Hutchison China MediTech (00013) shares increased over 5.3% after announcing positive results from a Phase III trial for a new treatment for autoimmune hemolytic anemia [3] - Geekplus Technology (02590) shares rose slightly by 0.51%, with a report highlighting its stable business model and growth potential due to AI applications [3] Group 4 - Xuan Bamboo Biotech (02575) shares surged over 11.6% after its drug, Pyrotinib, was included in the national medical insurance directory, providing new benefits for advanced breast cancer patients [4] Group 5 - Semiconductor equipment and materials stocks continued to rise, with significant gains for companies like Amkor Technology (AMKR.US) and Lam Research (LRCX.US) [5] - Chinese concept stocks mostly rose, with notable increases for Hesai (HSAI.US) and Pinduoduo (PDD.US), amid a bullish market sentiment [5] - Uber (UBER.US) and Lyft (LYFT.US) saw stock price increases following Nvidia's announcement of advancements in autonomous driving technology [5] Group 6 - Data center cooling stocks experienced a decline, with companies like Modine Manufacturing (MOD.US) and Johnson Controls (JCI.US) facing significant drops [6] - Copper stocks strengthened, with Freeport-McMoRan (FCX.US) and Southern Copper (SCCO.US) showing notable gains as copper futures reached a historic high [6] - The storage sector continued its upward trend, with SanDisk (SNDK.US) achieving a 27.56% increase after launching a new SSD product line [6] Group 7 - Alumis (ALMS.US) shares skyrocketed by 95.31% following positive results from clinical trials for its TYK2 inhibitor targeting psoriasis patients [7] - Tesla (TSLA.US) shares fell over 4.14% as BYD surpassed Tesla in electric vehicle sales in key European markets [7] - Zeta Global (ZETA.US) shares rose 9.83% after announcing a strategic partnership with OpenAI to enhance its product capabilities [7]

2026年1月7日，恒生医药ETF（159892）上涨2.94%，冲击三连阳。持仓股康方生物、和黄医药、翰森 制药涨超4%。 中信建投证券认为，国内上市药企正迎来创新收获期，呈现自主研发+海外BD双轮驱动格局。整体看， 中国药企从单一市场驱动转向全球价值创造，JPM大会将成为展示临床数据、洽谈海外合作的核心舞 台。 恒生医药ETF（159892）聚焦创新药、CXO及相关产业，港交所18A制度优势下覆盖众多创新标的（百 济神州、信达生物等），在创新药出海+商保目录等催化下有望延续估值修复行情。 消息面上，近日，国家药监局官方微信公号发文称，2025年我国已批准上市的创新药达76个，大幅超过 2024年全年48个，创历史新高。此外，2025年我国创新药对外授权交易总金额超过1300亿美元，授权交 易数量超过150笔，同样创历史新高。 ...

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 3%, currently up 3.1% at HKD 21.98, with a trading volume of HKD 44.32 million [1] Group 1: Clinical Research - On January 7, Hutchison China MediTech announced that its Syk inhibitor, Sola-pinib, has met the primary endpoint of durable hemoglobin (Hb) response during the 5 to 24 weeks treatment period in the ESLIM-02 study for adult patients with warm antibody autoimmune hemolytic anemia [1] - The ESLIM-02 study is a randomized, double-blind, placebo-controlled clinical trial conducted in China for adult patients with relapsed or refractory primary or secondary warm antibody autoimmune hemolytic anemia who have received at least one standard treatment [1] - The results of the Phase II portion of the ESLIM-02 study were published in The Lancet Haematology in January 2025 [1] Group 2: Future Plans - Hutchison China MediTech plans to submit a new drug application for Sola-pinib to the National Medical Products Administration of China in the first half of 2026 for the treatment of warm antibody autoimmune hemolytic anemia [1] - Complete data from the ESLIM-02 study will be presented at an upcoming academic conference [1]

Group 1 - The majority of Hong Kong pharmaceutical stocks experienced an increase, with 恒瑞医药 (Hengrui Medicine) and 和黄医药 (Hutchison China MediTech) rising over 3% [1] - 康龙化成 (Crown Bioscience), 石药集团 (Shijiazhuang Pharmaceutical Group), and 泰凌医药 (Tianling Pharmaceutical) saw increases of over 2% [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) has seen a stock increase of over 3%, currently trading at HKD 21.98, following the announcement of positive results from the ESLIM-02 study for its Syk inhibitor, selinexor, in treating warm antibody autoimmune hemolytic anemia in adults [1]. Group 1: Study Announcement - On January 7, Hutchison China MediTech announced that the ESLIM-02 study, a Phase III registration trial, has met its primary endpoint of durable hemoglobin response during the treatment period from week 5 to week 24 [1]. - The ESLIM-02 study is a randomized, double-blind, placebo-controlled clinical trial conducted in China, targeting adult patients with relapsed or refractory warm antibody autoimmune hemolytic anemia who have previously received at least one standard treatment [1]. - Results from the Phase II portion of the ESLIM-02 study were published in The Lancet Haematology in January 2025 [1]. Group 2: Future Plans - Hutchison China MediTech plans to submit a new drug application for selinexor to the National Medical Products Administration of China in the first half of 2026 for the treatment of warm antibody autoimmune hemolytic anemia [1]. - Complete data from the ESLIM-02 study will be presented at an upcoming academic conference [1].

Core Insights - The core viewpoint of the articles is that the Syk inhibitor, Solipnib, has shown promising results in the ESLIM-02 study for treating warm antibody autoimmune hemolytic anemia in adults, indicating a potential new treatment option for patients who have failed standard therapies [1][2]. Group 1: Study Results - The ESLIM-02 study has reached its primary endpoint of durable hemoglobin (Hb) response during the treatment period from week 5 to week 24 [1]. - In the II phase of the study, Solipnib demonstrated a significant overall response rate of 43.8% compared to 0% for the placebo in the first 8 weeks, and an overall response rate of 66.7% during the 24-week treatment period, including patients who crossed over from the placebo [1]. - The safety profile of Solipnib was reported to be good throughout the study [1]. Group 2: Expert Commentary - Professor Zhang Fengkui, a principal investigator of the ESLIM-02 study, highlighted the disease's heterogeneity and chronic relapsing nature, which severely impacts patients' quality of life and can be life-threatening if not effectively controlled [2]. - The positive topline results of the ESLIM-02 study underscore the potential of Solipnib to provide rapid and durable hemoglobin responses for patients with limited treatment options after standard therapy failure [2]. - The complete data from the ESLIM-02 study will be submitted for presentation at an upcoming academic conference [2]. Group 3: Future Plans - The company plans to submit a new drug application for Solipnib to the National Medical Products Administration of China in the first half of 2026 for the treatment of warm antibody autoimmune hemolytic anemia [2].